Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin, Radiesse, and Belotero for Photoaging
NCT05039723Phase 4Completed
- Sponsor
- Main Line Center for Laser Surgery
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Injectable Hydrogels, Implantable Devices, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A, calcium hydroxyapatite and belotero in photoaging, sponsored by Main Line Center for Laser Surgery. Primary endpoint: FACE-Q Subject Satisfaction at 3 months. Started Sep 2021; status: completed.
02
Drugs
botulinum toxin type Acalcium hydroxyapatitebelotero
03
Conditions
photoaging
Beyond the preview
Go deeper on NCT05039723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039723.